CD274 and neoplasm: The secondary objectives were: (1) to non-invasively characterize the spatial and temporal heterogeneity of PD-L1; and (2) to identify the relationship between 89Zr-DFO-Atezolizumab uptake, PD-L1 IHC staining, and tumor-infiltrating immune cell populations.